PPDTM CorEvitasTM Obesity (OBR) Drug Effectiveness and Safety Registry

NCT07598981 | Enrolling By Invitation

• 1 other identifier: CorEvitas-OBR-300
• Study Type: observational
• Target: 10,000
• Locations: 1 country
• Sites: 1

Brief Summary

The design is an open-ended prospective observational (non-interventional) registry for subjects living with excess weight or obesity under the care of a qualified provider with documented experience treating patients with obesity

Conditions

Obesity

Outcome Measures

Primary Outcomes (1)

• Obesity Epidemiology and presentation

  The major clinical outcome include an assessment of the epidemiology of Obesity. This will be determined using PROs and ClinROs which will be included as part of the case report forms.

  Every 6 months for 10 years

Interventions

Biospecimen collection OTHER

Blood Samples will be collected from subjects. This is optional for the participating subjects

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Subjects enrolled in this registry will be treated according to routine clinical care; the assignment of subjects to any treatment will not be determined in advance by the protocol and will be clearly separated from the decision to include subjects in the registry

You may qualify if:

• To be eligible to participate in this registry, an individual must meet all of the following criteria:
• In the opinion of the investigator, the subject is considered a suitable candidate for treatment with a commercially available systemic obesity medication (see Enrollment Eligible Treatments). While subjects do not need to start an obesity medication at the time of registry enrollment, those prescribed a GLP-based or non-GLP-based obesity medication must be initiating the medication for the first time.
• Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable laws of the jurisdiction in which the research is being conducted at the time of enrollment.
• Is willing and able to consent to participation in the registry.
• Is willing and able to complete registry-related forms electronically via personal devices
• Is willing and able to provide first name, last name, email address, language, and primary time zone for electronic data collection account creation.
• For US subjects only, is willing and able to provide Personally Identifiable Information which includes full legal name, sex at birth, date of birth, and home address zip code.

You may not qualify if:

• An individual who meets any of the following criteria will be excluded from participation in the registry:
• Has Type 2 diabetes (T2D).
• Is participating or planning to participate in a blinded clinical trial.

Sponsors & Collaborators

• CorEvitas: lead

Study Sites (1)

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

Location

MeSH Terms

Conditions

Obesity

Condition Hierarchy (Ancestors)

Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Year
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 28, 2026
• First Posted: May 20, 2026
• Study Start: October 29, 2025
• Primary Completion (Estimated): December 31, 2099
• Study Completion (Estimated): December 31, 2099
• Last Updated: May 20, 2026

Record last verified: 2026-01

Locations

US (1)